Q32 Bio's Cash, Cash Equivalents, And Short-term Investments Of $107.6M As Of June 30, 2024, Expected To Provide Financial Runway Through Four Phase 2 Clinical Milestones And Into Mid-2026
Q32 Bio's Cash, Cash Equivalents, And Short-term Investments Of $107.6M As Of June 30, 2024, Expected To Provide Financial Runway Through Four Phase 2 Clinical Milestones And Into Mid-2026
截至2024年6月30日，Q32生物的現金、現金等價物和短期投資爲1.076億美元，預計將支持通過四個2期臨床里程碑，直至2026年中期的財務運營。
Q32 Bio's Cash, Cash Equivalents, And Short-term Investments Of $107.6M As Of June 30, 2024, Expected To Provide Financial Runway Through Four Phase 2 Clinical Milestones And Into Mid-2026
截至2024年6月30日，Q32生物的現金、現金等價物和短期投資爲1.076億美元，預計將支持通過四個2期臨床里程碑，直至2026年中期的財務運營。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。